Detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with chronic lymphocytic leukemia (CLL)
Identifying and tracking known chromosome abnormalities in patients with CLL and tracking response to therapy
Distinguishing patients with 11;14 translocations who have leukemic phase of mantle cell lymphoma from patients who have CLL
Detecting patients with atypical CLL or other forms of lymphoma associated with translocations between IGH and BCL2, BCL3, MYC, or other partner genes
This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred. See the Method Description for specific details.
Indicate if the entire panel is to be performed. The entire panel is suggested for patients with a new diagnosis of chronic lymphocytic leukemia (CLL). If the patient is being tracked for known abnormalities or disease progression, indicate which probes should be used.
Panel includes testing for the following abnormalities using the probes listed:
6q-, D6Z1/MYB
11q-, D11Z1/ATM
+12, D12Z3/MDM2
13q-, D13S319/LAMP1
17p-, TP53/D17Z1
t(11;14), CCND1/IGH
When an IGH rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of t(14;18)(q32;q21) IGH/BCL2 and t(14;19)(q32;q13) IGH/BCL3.
This assay detects abnormalities observed in the blood and bone marrow of patients with CLL. If a paraffin-embedded tissue sample is received, this test will be cancelled and SLLF / Small Lymphocytic Lymphoma, FISH, Tissue will be added and performed as the appropriate test.
